Secretary of State visits IBEC at the Barcelona Science Park Blog Post

This morning, Secretary of State for Research, Development and Innovation, Carmen Vela, visited the Institute for Bioengineering of Catalonia (IBEC) at PCB, after taking part in the opening ceremony of the conference ‘Future Tools for Biomedical Research. In Vitro, in Silico and in Vivo Disease Modeling‘, organized by B·Debate, International Center for Scientific Debate – an initiative of Biocat and “la Caixa” – jointly with IBEC. 

 

Sylvie Bove, new CEO of EIT Health Blog Post

Sylvie Bove has been appointed as new CEO of the EIT Health, the Knowledge and Innovation Community (KIC) for healthy living and active aging, promoted by the European Institute of Innovation and Technology (EIT). The Spanish node, EIT Health Spain, headed by the University of Barcelona (UB) with the support from Biocat, has its headquarters at Barcelona Science Park (PCB) and is composed of 50 core partners and 90 associate partners from the public and private sectors, leaders in their fields and committed to innovation in health. Bove took on the position on September 1

 

Anna Taratiel explores the relationship between art and science through her art work at the Barcelona Science Park Blog Post

Anna Taratiel, one of the leading representatives of the global movement of the street art, has finished the work at the  Barcelona Science Park (PCB) that was started last October. It is a large dimensions mural covering the walls of the central aisle –measuring over 80 meters in length and that connects the Cluster I and Cluster II PCB buildings, where many laboratories of the different centers, companies and research institutes installed in the park converge.

 

 

Genetic “editing” a new tool to fight inherited disease Blog Post

Researchers at the Hospital Clínic, IDIBAPS, the Hospital Sant Joan de Deu and the Institute for Bioengineering of Catalonia (IBEC) have participated in a study, led by Dr. Juan Carlos Izpisúa Belmonte of the Gene Expression Laboratory at California’s Salk Institute, that uses molecular scissors to remove mitochondrial mutations in mouse eggs. In the study, published today in the journal Cell (doi: 10.1016/j.cell.2015.03.051), researchers developed a simple technique to eliminate mitochondrial mutations in eggs or embryos at an early stage of development.

SOM Biotech develops a drug for Amyloidosis in collaboration with the Vall d’Hebron Research Institute Blog Post

The and the biopharmaceutical , based at the Parc Científic de Barcelona (PCB), have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts with the execution of a proof of concept in 20 healthy voluntiers and patients affected by the polineuropatic form of the disease – which will confirm the efficacy and safety of compound SOM0226. The product, a repositioned drug developed by SOM Biotech, may be effective for all variants of the ATTR and has been designated recently orphan drug by the Food and Drug Administration (FDA) of United States.